UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 4, 2009
Lpath, Inc.
(Exact name of registrant specified in charter)
Nevada | | 000-50344 | | 16-1630142 |
(State of Incorporation) | | (Commission File Number) | | (IRS Employer |
| | | | Identification No.) |
6335 Ferris Square, Suite A, San Diego, CA 92121
(Address of principal executive offices) (Zip Code)
(858) 678-0800
Issuer’s Telephone Number
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 7.01 Regulation FD Disclosure
Lpath, Inc. (the “Company”) hosted a conference call on June 4, 2009 at 4:30p.m. Eastern time (1:30 p.m. Pacific time), to provide a business review and clinical update. Callers can access a telephone replay of the call until June 14, 2009 by dialing the following numbers (no passcode is required):
Toll-free replay number: 1-800-374-1375
International replay number: 1-402-220-0682
The information in this Item only, is furnished pursuant to Item 7.01 of this Form 8-K. Consequently, it is not deemed “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended, if such subsequent filing specifically references this Form 8-K.
Item 8.01 Other Events
The Company announced that it received a grant of up to $3 million over a 3-year period from the National Cancer Institute for the development of the Company’s cancer drug candidate ASONEP. A copy of the press release is attached hereto as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits.
Exhibits
99.1 | | Press Release dated June 4, 2009. |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Lpath, Inc. |
| |
| |
| By: | /s/Scott Pancoast |
| Name: Scott Pancoast |
| Title: President and Chief Executive Officer |
| Dated: June 5, 2009 |
3
